Literature DB >> 1503916

Phase I study of intra-arterial interleukin-2 in squamous cell carcinoma of the head and neck.

M E Gore1, P Riches, K MacLennan, M O'Brien, J Moore, G Dadian, A Lorentzos, R Garth, E Moskovic, D Archer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1503916      PMCID： PMC1977791          DOI： 10.1038/bjc.1992.278

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  14 in total

1.  Infectious complications of interleukin 2 therapy.

Authors:  J R Hardy; J Moore; A Lorentzos; E Ellis; B Jameson; M E Gore
Journal:  Cytokine       Date:  1990-07       Impact factor: 3.861

2.  Splenic versus hepatic artery infusion of interleukin-2 in patients with liver metastases.

Authors:  G M Mavligit; A A Zukiwski; J U Gutterman; P Salem; C Charnsangavej; S Wallace
Journal:  J Clin Oncol       Date:  1990-02       Impact factor: 44.544

3.  Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients.

Authors:  S A Rosenberg; M T Lotze; J C Yang; P M Aebersold; W M Linehan; C A Seipp; D E White
Journal:  Ann Surg       Date:  1989-10       Impact factor: 12.969

4.  Interleukin-2 augments natural killer cell activity.

Authors:  C S Henney; K Kuribayashi; D E Kern; S Gillis
Journal:  Nature       Date:  1981-05-28       Impact factor: 49.962

5.  Interleukin-2 injected around tumor-draining lymph nodes in head and neck cancer.

Authors:  G Cortesina; A De Stefani; E Galeazzi; G P Cavallo; C Jemma; M Giovarelli; S Vai; G Forni
Journal:  Head Neck       Date:  1991 Mar-Apr       Impact factor: 3.147

6.  Reporting results of cancer treatment.

Authors:  A B Miller; B Hoogstraten; M Staquet; A Winkler
Journal:  Cancer       Date:  1981-01-01       Impact factor: 6.860

7.  Fibrinolysis, thrombocytopenia, and coagulation abnormalities complicating high-dose interleukin-2 immunotherapy.

Authors:  J D Fleischmann; W B Shingleton; C Gallagher; O D Ratnoff; A Chahine
Journal:  J Lab Clin Med       Date:  1991-01

8.  Serum interleukin-2 levels in relation to the neuroendocrine status in cancer patients.

Authors:  P Lissoni; G Tancini; F Rovelli; G Cattaneo; C Archili; S Barni
Journal:  Br J Cancer       Date:  1990-11       Impact factor: 7.640

9.  Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.

Authors:  E A Grimm; A Mazumder; H Z Zhang; S A Rosenberg
Journal:  J Exp Med       Date:  1982-06-01       Impact factor: 14.307

10.  Expression of interleukin 2 receptors on activated human B cells.

Authors:  T A Waldmann; C K Goldman; R J Robb; J M Depper; W J Leonard; S O Sharrow; K F Bongiovanni; S J Korsmeyer; W C Greene
Journal:  J Exp Med       Date:  1984-11-01       Impact factor: 14.307
View more
  4 in total

1.  Head and neck chemotherapy.

Authors: 
Journal:  AJNR Am J Neuroradiol       Date:  2001-09       Impact factor: 3.825

Review 2.  Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer.

Authors:  Ruth Whittington; Diana Faulds
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

Review 3.  Interferons and other cytokines in head and neck cancer.

Authors:  V K Hamasaki; E E Vokes
Journal:  Med Oncol       Date:  1995-03       Impact factor: 3.064

4.  Temporary regression of recurrent squamous cell carcinoma of the head and neck is achieved with a low but not with a high dose of recombinant interleukin 2 injected perilymphatically.

Authors:  G Cortesina; A De Stefani; E Galeazzi; G P Cavallo; F Badellino; G Margarino; C Jemma; G Forni
Journal:  Br J Cancer       Date:  1994-03       Impact factor: 7.640
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.